Skip to main content
Journal cover image

Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.

Publication ,  Journal Article
Choueiri, TK; Chen, M-H; D'Amico, AV; Sun, L; Nguyen, PL; Hayes, JH; Robertson, CN; Walther, PJ; Polascik, TJ; Albala, DM; Moul, JW
Published in: Cancer
April 15, 2010

BACKGROUND: This report evaluated whether biochemical recurrence (BCR) as a time-dependent covariate (t) after radical prostatectomy (RP) for prostate cancer was associated with the risk of death and whether salvage therapy with radiotherapy (RT) and/or hormonal therapy (HT) can lessen this risk METHODS: This was a retrospective cohort study of 3071 men who underwent RP at Duke University between 1988 and 2008 and had complete follow-up data. A Cox regression multivariable analysis was used to determine whether BCR (t) was associated with the risk of death in men after adjusting for age, prostatectomy findings, and the use of salvage RT and/or HT. RESULTS: After a median follow-up of 7.4 years, 546 (17.8%) men experienced BCR and 454 (14.8%) died. The median follow-up after prostate-specific antigen (PSA) failure was 11.2 years (interquartile range, 5.8-16.0 years). BCR (t) was associated with an increased risk of death (adjusted hazards ratio [AHR], 1.03; 95% confidence interval [95% CI], 1.004-1.06 [P = .025]). In men who experienced BCR, a PSA doubling time <6 months was associated with an increased risk of death (AHR, 1.55; 95% CI, 1.15-2.1 [P = .004]); whereas a decrease in the risk of death was observed in men who received RT (AHR, 0.58; 95% CI, 0.40-0.58 [P = .002]) or HT (AHR, 0.56; 95% CI, 0.37-0.84 [P = .005]) after BCR. CONCLUSIONS: The occurrence of BCR was found to increase the risk of death in men undergoing RP for prostate cancer, and this risk appeared to increase as the time to BCR shortened. However, the addition of RT and/or HT in men with BCR significantly lowered this risk.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

April 15, 2010

Volume

116

Issue

8

Start / End Page

1887 / 1892

Location

United States

Related Subject Headings

  • Treatment Failure
  • Time Factors
  • Salvage Therapy
  • Risk
  • Recurrence
  • Radiotherapy, Adjuvant
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Postoperative Period
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Choueiri, T. K., Chen, M.-H., D’Amico, A. V., Sun, L., Nguyen, P. L., Hayes, J. H., … Moul, J. W. (2010). Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer, 116(8), 1887–1892. https://doi.org/10.1002/cncr.25013
Choueiri, Toni K., Ming-Hui Chen, Anthony V. D’Amico, Leon Sun, Paul L. Nguyen, Julia H. Hayes, Cary N. Robertson, et al. “Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.Cancer 116, no. 8 (April 15, 2010): 1887–92. https://doi.org/10.1002/cncr.25013.
Choueiri TK, Chen M-H, D’Amico AV, Sun L, Nguyen PL, Hayes JH, et al. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010 Apr 15;116(8):1887–92.
Choueiri, Toni K., et al. “Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.Cancer, vol. 116, no. 8, Apr. 2010, pp. 1887–92. Pubmed, doi:10.1002/cncr.25013.
Choueiri TK, Chen M-H, D’Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010 Apr 15;116(8):1887–1892.
Journal cover image

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

April 15, 2010

Volume

116

Issue

8

Start / End Page

1887 / 1892

Location

United States

Related Subject Headings

  • Treatment Failure
  • Time Factors
  • Salvage Therapy
  • Risk
  • Recurrence
  • Radiotherapy, Adjuvant
  • Prostatic Neoplasms
  • Prostatectomy
  • Prostate-Specific Antigen
  • Postoperative Period